Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

AIDS

Volumn 18, Issue 7, 2004, Pages 991-1001

  Leung, Louisa ^a   Srivastava, Indresh K ^a   Kan, Elaine ^a   Legg, Harold ^a   Sun, Yide ^a   Greer, Catherine ^a   Montefiori, David C ^b   Megede, Jan Zur ^a   Barnett, Susan W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA vaccine; Env; Gag; HIV 1; Prime boost

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 140; MUTANT PROTEIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; PLASMID DNA; PROTEIN P55; PROTEINASE; VIRUS ENVELOPE PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; BABOON; CONTROLLED STUDY; FEMALE; GENE CASSETTE; GENE CONSTRUCT; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS EXPRESSION; VIRUS GENE; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODY AFFINITY; CELL DIVISION; DNA, VIRAL; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV-1; IMMUNIZATION; IMMUNIZATION, SECONDARY; MUTAGENESIS, INSERTIONAL; PAPIO; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA;

EID: 2342520612     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404300-00006     Document Type: Article

References (33)

1. Heeney J, Akerblom L, Barnett S, Bogers W, Davis D, Fuller D, et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999, 66:189-195.
2. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis 2000, 182:579-589.
3. Ulmer JB, Donnelly JJ, Liu MA. DNA vaccines: immunogenicity and preclinical efficacy. In: Handbook of Experimental Pharmacology. Edited by Perlmann P, Wigzell H. Berlin: Springer-Verlag, 1999:43-55.
4. Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 2000, 55:1-74.
5. Shiver JW, Davies ME, Perry HC, Freed DC, Liu MA. Humoral and cellular immunities elicited by HIV-1 vaccination. J Pharm Sci 1996, 85:1317-1324.
6. Otten GR, Doe B, Schaefer M, Chen M, Selby MJ, Goldbeck C, et al. Relative potency of cellular and humoral immune responses by DNA vaccination. Intervirology2000, 43:227-232.
7. Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997, 15:869-873.
8. Fuller DH, Corb MM, Barnett S, Steimer K, Haynes JR. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997, 15:924-926.
9. Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekutis C, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997, 94:9378-9383.
10. Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999, 5:526-534.
11. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
12. Cherpelis S, Srivastava I, Gettie A, Jin X, Ho DD, Barnett SW, et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 2001, 75:1547-1550.
13. Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 2001, 75:2462-2467.
14. Ulmer JB. An update on the state of the art of DNA vaccines. Curr Opin Drug Discov Dev 2001, 4:192-197.
15. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996, 6:315-324.
16. zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000, 74:2628-2635.
17. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. J Virol 2002, 76:2835-2847.
18. Scandella CJ, Kilpatrick J, Lidster W, Parker C, Moore JP, Moore GK, et al. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res Hum Retroviruses 1993, 9:1233-1244.
19. Budzko D, Madden DL, London WT, Sever JL. Improved separation of rhesus monkey lymphocytes with Percoll. Lab Invest 1985, 53:586-588.
20. Barr PJ, Steimer KS, Sabin EA, Parkes D, George-Nascimento C, Stephans JC, et al. Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae. Vaccine 1987, 5:90-101.
21. Abrignani S, Montagna D, Jeannet M, Wintsch J, Haigwood NL, Shuster JR, et al. Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc Natl Acad Sci USA 1990, 87:6136-6140.
22. Haigwood NL, Shuster JR, Moore GK, Lee H, Skiles PV, Higgins KW, et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses 1990, 6:855-869.
23. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000, 16:2019-2035.
24. Montefiori DC, Robinson WE, Jr, Schuffman SS, Mitchell WM. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988, 26:231-235.
25. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000, 165:2850-2858.
26. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
27. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000, 97:811-816.
28. Briones M, Singh M, Ugozzoli M, Kazzaz J, Klakamp S, Ott C, et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 2001, 18:709-711.
29. O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, et al. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J Virol 2001, 75:9037-9043.
30. Barnett S, Otten C, Srivastava I, zur Megede J, Lian Y, Schaefer M, et al. Enhanced DNA prime-protein boost vaccines induce potent immune responses against HIV-1. In XIII Cent Gardes Symposium on Retroviruses of Human AIDS and Related Diseases. Annecy, France. Edited by M Girard, M Vicari, B Dodet. October, 2003:145-153.
31. Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000, 7:2105-2112.
32. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75:5526-5540.
33. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003, 77:5889-5901.